) announced that the first patient has been dosed in a phase I/II
study of pipeline candidate, BL-7010.
BL-7010 is being evaluated for the treatment of celiac
disease. In this double-blind, placebo-controlled, dose
escalation, two-part study, the primary endpoint is the
evaluation of the safety of single and repeated ascending doses
of BL-7010 in well-controlled celiac patients. Secondary endpoint
is the assessment of systemic exposure of BL-7010 in the
patients. Results will be out in mid 2014. This study
will be followed by an efficacy study which will start in the
second half of 2014.
We note that BL-7010 is developed by BioLineRx under a
worldwide exclusive license agreement with Univalor.
Apart from BL-7010, BioLineRx's pipeline looks promising with
candidates like BL-5010 (non-surgical removal of skin lesions, a
pivotal CE-mark registration trial to start in early 2014);
BL-1040 (preventing pathological cardiac remodelling following a
myocardial infarction, currently in a pivotal CE-Mark
registration trial) and BL-8040 (acute myeloid leukemia (AML) and
other hematological cancer indications, currently in a phase II
Earlier this week, BioLineRx announced positive initial
results on BL-8040 which is being evaluated in a multicenter,
open-label, phase II study for treating adults suffering from
relapsed/refractory AML. Interim results are expected in the
second quarter of 2014 and final study results are expected in
the second half of 2014.
BioLineRx carries a Zacks Rank #3 (Hold). Some better-ranked
Questcor Pharmaceuticals Inc.
Jazz Pharmaceuticals plc
). Each stock carries a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
BIOLINE RX LTD (BLRX): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
QUESTCOR PHARMA (QCOR): Free Stock Analysis
To read this article on Zacks.com click here.